CGS Stock Overview
Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.60|
|52 Week High||AU$2.68|
|52 Week Low||AU$1.35|
|1 Month Change||-10.14%|
|3 Month Change||-30.04%|
|1 Year Change||15.16%|
|3 Year Change||717.95%|
|5 Year Change||39.91%|
|Change since IPO||219.00%|
Recent News & Updates
Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
|CGS||AU Healthcare Services||AU Market|
Return vs Industry: CGS exceeded the Australian Healthcare Services industry which returned -34.3% over the past year.
Return vs Market: CGS exceeded the Australian Market which returned -11.3% over the past year.
|CGS Average Weekly Movement||8.4%|
|Healthcare Services Industry Average Movement||11.2%|
|Market Average Movement||9.7%|
|10% most volatile stocks in AU Market||16.3%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: CGS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CGS's weekly volatility (8%) has been stable over the past year.
About the Company
Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The company’s services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments.
Cogstate Fundamentals Summary
|CGS fundamental statistics|
Is CGS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CGS income statement (TTM)|
|Cost of Revenue||US$16.84m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Jul 28, 2022
|Earnings per share (EPS)||0.056|
|Net Profit Margin||23.30%|
How did CGS perform over the long term?See historical performance and comparison
Is CGS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 6/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CGS?
Other financial metrics that can be useful for relative valuation.
|What is CGS's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does CGS's PE Ratio compare to its peers?
|CGS PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
PME Pro Medicus
PSQ Pacific Smiles Group
CAJ Capitol Health
MVF Monash IVF Group
Price-To-Earnings vs Peers: CGS is good value based on its Price-To-Earnings Ratio (19.7x) compared to the peer average (113.5x).
Price to Earnings Ratio vs Industry
How does CGS's PE Ratio compare vs other companies in the Global Healthcare Services Industry?
Price-To-Earnings vs Industry: CGS is good value based on its Price-To-Earnings Ratio (19.7x) compared to the Global Healthcare Services industry average (38.9x)
Price to Earnings Ratio vs Fair Ratio
What is CGS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||19.7x|
|Fair PE Ratio||38.8x|
Price-To-Earnings vs Fair Ratio: CGS is good value based on its Price-To-Earnings Ratio (19.7x) compared to the estimated Fair Price-To-Earnings Ratio (38.8x).
Share Price vs Fair Value
What is the Fair Price of CGS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CGS (A$1.6) is trading below our estimate of fair value (A$3.98)
Significantly Below Fair Value: CGS is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: CGS is good value based on its PEG Ratio (0.7x)
Discover undervalued companies
How is Cogstate forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CGS's forecast earnings growth (27% per year) is above the savings rate (1.8%).
Earnings vs Market: CGS's earnings (27% per year) are forecast to grow faster than the Australian market (6% per year).
High Growth Earnings: CGS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CGS's revenue (24.8% per year) is forecast to grow faster than the Australian market (5.2% per year).
High Growth Revenue: CGS's revenue (24.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CGS's Return on Equity is forecast to be high in 3 years time (27.1%)
Discover growth companies
How has Cogstate performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CGS has a large one-off gain of $2.4M impacting its December 31 2021 financial results.
Growing Profit Margin: CGS's current net profit margins (23.3%) are higher than last year (1.2%).
Past Earnings Growth Analysis
Earnings Trend: CGS's earnings have grown significantly by 51% per year over the past 5 years.
Accelerating Growth: CGS's earnings growth over the past year (2812.4%) exceeds its 5-year average (51% per year).
Earnings vs Industry: CGS earnings growth over the past year (2812.4%) exceeded the Healthcare Services industry 8%.
Return on Equity
High ROE: CGS's Return on Equity (34.7%) is considered high.
Discover strong past performing companies
How is Cogstate's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: CGS's short term assets ($37.2M) exceed its short term liabilities ($15.5M).
Long Term Liabilities: CGS's short term assets ($37.2M) exceed its long term liabilities ($8.5M).
Debt to Equity History and Analysis
Debt Level: CGS has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CGS's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: CGS's debt is well covered by operating cash flow (541.3%).
Interest Coverage: CGS's interest payments on its debt are well covered by EBIT (187.3x coverage).
Discover healthy companies
What is Cogstate current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CGS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CGS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CGS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CGS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Bradley O'Connor, also known as Brad, B.Bus, CA, has been the Chief Executive Officer and Managing Director of Cogstate Limited since December 1, 2005 and served as its Chief Financial Officer since Ma...
CEO Compensation Analysis
Compensation vs Market: Brad's total compensation ($USD1.08M) is above average for companies of similar size in the Australian market ($USD603.06K).
Compensation vs Earnings: Brad's compensation has been consistent with company performance over the past year.
Experienced Management: CGS's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: CGS's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cogstate Limited's employee growth, exchange listings and data sources
- Name: Cogstate Limited
- Ticker: CGS
- Exchange: ASX
- Founded: 1999
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: AU$276.522m
- Shares outstanding: 173.37m
- Website: https://www.cogstate.com
Number of Employees
- Cogstate Limited
- 161 Collins Street
- Level 2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/25 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.